文献速递泌尿生殖腹部CT

术前增强CT主动脉-病灶密度差鉴别恶性与良性嗜酸细胞性肾肿瘤的验证研究

Validation of aorta-lesion-attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors.
PubMed 文献 · Abdom Radiol (NY) · 2021-03-04

本研究在第二组肾切除患者中验证术前增强CT测量的主动脉-病灶密度差(ALAD)鉴别恶性肾肿瘤与嗜酸细胞瘤的能力。结论认为ALAD的鉴别能力较训练队列有所下降但仍显著,支持进一步研究其在性质未定的嗜酸细胞性肿瘤管理中的作用。

要点

  • 肾图期ALAD鉴别恶性病理与嗜酸细胞瘤的AUC在验证队列为0.72(95%CI 0.63-0.82)。
  • 肾图期ALAD鉴别嫌色细胞癌与嗜酸细胞瘤的敏感度在验证队列为67%,特异度67%。
  • 验证队列患者较训练队列年龄更大、肿瘤更大、分期更高,ALAD鉴别能力有所下降。

诊断标准与关键数值

  • 肾图期ALAD鉴别恶性病理与嗜酸细胞瘤:训练队列敏感度84%、特异度86%、PPV 98%、NPV 33%;验证队列敏感度73%、特异度67%、PPV 91%、NPV 35%。
  • 验证队列肾图期ALAD鉴别恶性病理与嗜酸细胞瘤的AUC为0.72(95%CI 0.63-0.82)。
  • 肾图期ALAD鉴别嫌色细胞癌与嗜酸细胞瘤:训练队列敏感度100%、特异度86%、PPV 75%、NPV 100%;验证队列敏感度67%、特异度67%、PPV 43%、NPV 84%。
  • 验证队列肾图期ALAD鉴别嫌色细胞癌与嗜酸细胞瘤的AUC为0.72(95%CI 0.48-0.96)。

临床应用与阅片要点

  • 肾图期ALAD可用于术前CT鉴别恶性肾肿瘤与嗜酸细胞瘤,验证队列中鉴别恶性病理与嗜酸细胞瘤的AUC为0.72。
  • 验证队列中ALAD鉴别嫌色细胞癌与嗜酸细胞瘤的AUC为0.72(95%CI 0.48-0.96),敏感度和特异度均为67%。
  • 与训练队列相比,验证队列患者年龄更大(62岁 vs 59岁)、肿瘤更大(3.7 cm vs 2.7 cm)、T1a期比例更低(59% vs 79%),ALAD鉴别能力有所下降。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We previously noted that the aorta-lesion-attenuation difference (ALAD) determined on CT scan discriminated well between chromophobe RCC and oncocytoma. The current evaluation seeks to validate these initial findings in a second cohort of nephrectomy patients.

METHODS: A retrospective review of preoperative CT scans and surgical pathology was performed on patients undergoing nephrectomy for small, solid renal masses. ALAD was calculated by measuring the difference in Hounsfield units (HU) between the aorta and the lesion of interest on the same image slice on preoperative CT scan. The discriminative ability of ALAD to differentiate malignant pathology from oncocytoma was evaluated by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under curve (AUC) using ROC analysis.

RESULTS: Twenty-one preoperative CT scans and corresponding pathology reports were reviewed and included in the validation cohort. ALAD values were calculated during the excretory and nephrographic phases. Compared to the training cohort, patients in the validation cohort were significantly older (62 versus 59 years old), had larger tumors (3.7 versus 2.7 cm), and higher stage disease (59% versus 79% T1a disease). Nephrographic ALAD was able to differentiate malignant pathology from oncocytoma in the training and validation cohorts with a sensitivity of 84% versus 73%, specificity of 86% and 67%, PPV of 98% versus 91%, and NPV of 33% versus 35%. The AUC for malignant pathology versus oncocytoma in the validation cohort was 0.72 (95% CI 0.63-0.82). Nephrographic ALAD was able to differentiate chromophobe RCC from oncocytoma in the training and validation cohorts with a sensitivity of 100% versus 67%, specificity of 86% versus 67%, PPV of 75% versus 43%, and NPV of 100% versus 84%. The AUC for chromophobe RCC versus oncocytoma in the validation cohort was 0.72 (95% CI 0.48-0.96).

CONCLUSIONS: The ability of ALAD to discriminate between chromophobe RCC and oncocytoma was diminished in the validation cohort compared to the training cohort, but remained significant. The current findings support further investigation in the role of ALAD in the management of patients with indeterminate diagnoses of oncocytic neoplasm.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Grajo JR, Batra NV, Bozorgmehri S, et al. Validation of aorta-lesion-attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors. Abdom Radiol (NY). 2021. PMID: 33665734. doi:10.1007/s00261-021-02971-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。